倍他乐克联合通心络胶囊治疗冠心病心绞痛的临床效果

Clinical effect of betaloc combined with Tongxinluo capsule in treatment of angina pectoris of coronary heart disease

目的系统评价倍他乐克联合通心络胶囊治疗冠心病心绞痛的临床效果。方法选择我院收治的冠心病心绞痛患者96例,随机分为研究组和对照组,各48例。对照组患者在常规治疗的基础上给予倍他乐克治疗,研究组患者在对照组基础上联合使用通心络胶囊治疗,观察两组患者的临床疗效。结果研究组患者临床总有效率为95.83%(46/48),明显高于对照组的83.33%(40/48)(P<0.05);治疗前,两组TG、TC、HDL、LDL水平比较,差异无统计学意义(P>0.05);治疗后,两组TG、TC、LDL均降低,HDL升高,且研究组TG、TC、LDL水平低于对照组,HDL水平高于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异不显著(P>0.05)。结论倍他乐克联合通心络胶囊治疗冠心病心绞痛患者临床效果显著,不良反应少,安全性高。

Objective To evaluate the clinical effect of betaloc combined with tongxinluo capsule in treating angina peetoris of coronary heart disease. Methods Ninety-six patients with angina pectoris of coronary heart disease treated in our hospital were selected and randomly divided into study group and control group, with 48 cases in each group. The control group received betaloe on the basis of the routine treatment, while the study group received Tongxinluo capsule on the basis of the control group, the clinical efficacy of the two groups were observed. Results The clinical total effective rate of the study group was 95.83% （46/48）, which was significantly higher than 83.33% （40/48） of the control group （P〈0.05）. Before treatment, there was no significant difference on the levels of TG, TC, HDL and LDL between the two groups （P〉 0.05）; after treatment, the levels of TG, TC and LDL in the two groups were lower, and HDL was higher than those before treatment, and the levels of TG, TC and LDL in the study group were lower and HDL was higher than those in the control group （P〈0.05）. There was no significant difference on the incidence rate of adverse reactions between the two groups （/9〉 0.05）. Conclusion Betaloc combined with Tongxinluo capsule in the treatment of angina pectoris of coronary heart disease has obvious clinical effect, with less adverse reactions and high security.